Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Documenti analoghi

• Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
  di: Chaturvedi, Anuhar, et al.
  Pubblicazione: (2020)
• In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
  di: Chaturvedi, Anuhar, et al.
  Pubblicazione: (2019)
• Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
  di: Chaturvedi, A, et al.
  Pubblicazione: (2017)
• Novel IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia
  di: Okoye-Okafor, Ujunwa C., et al.
  Pubblicazione: (2015)
• IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors
  di: Molenaar, Remco J., et al.
  Pubblicazione: (2018)